Correlation of Mammographic Microcalcifications with Final Surgical Pathology After Neoadjuvant Chemotherapy for Breast Cancer

Ann Surg Oncol. 2023 Jul;30(7):4123-4131. doi: 10.1245/s10434-023-13367-w. Epub 2023 Apr 8.

Abstract

Introduction: Imaging guidelines for post-neoadjuvant chemotherapy (NAC) breast cancer patients lack specificity on appropriateness and utility of individual modalities for surgical planning. Microcalcifications confound mammographic interpretation. We examined the correlation between the mammographic extent of microcalcifications present post-NAC, corresponding magnetic resonance imaging (MRI) lesions, and definitive surgical pathology.

Methods: In this retrospective cohort study, patients with calcifications on mammography were collected from a database of consecutive breast cancer patients receiving NAC. The primary objective was to determine the correlation between maximum dimension of post-NAC calcifications with surgical pathology (invasive disease, tumor bed, and ductal carcinoma in situ [DCIS]), stratified by tumor receptor subgroup. Secondarily, we examined the correlation of residual disease with MRI mass enhancement (ME) and non-ME (NME). Pearson's correlation coefficient was used to evaluate statistical significance (strong: R2 ≥70%; moderate: R2=25-70%; weak: R2 ≤25%).

Results: Overall, 186 patients met the inclusion criteria. Mammographic calcifications correlated poorly with invasive disease (R2 = 10.8%), overestimating by 57%. In patients with calcifications on mammography, MRI ME and NME correlated weakly with the maximum dimension of invasive disease and DCIS. In triple-negative breast cancer (TNBC) patients, invasive disease correlated strongly with the maximum dimension of calcifications (R2 = 83%) and moderately with ME (R2 = 37.7%) and NME (R2 = 28.4%).

Conclusion: Overall, current imaging techniques correlate poorly and overestimate final surgical pathology. This poor correlation may lead to uncertainty in the extent of required surgical excision and the exclusion of potential candidates for non-surgical management in ongoing trials. TNBCs would be good candidates for these trials given the stronger observed correlations between pathology and imaging.

MeSH terms

  • Breast Neoplasms* / diagnostic imaging
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / surgery
  • Calcinosis* / diagnostic imaging
  • Calcinosis* / pathology
  • Carcinoma, Intraductal, Noninfiltrating* / diagnostic imaging
  • Carcinoma, Intraductal, Noninfiltrating* / drug therapy
  • Carcinoma, Intraductal, Noninfiltrating* / surgery
  • Female
  • Humans
  • Magnetic Resonance Imaging / methods
  • Mammography
  • Neoadjuvant Therapy
  • Pathology, Surgical*
  • Retrospective Studies
  • Triple Negative Breast Neoplasms*